Building On Spiriva, BI Buys Funxional’s Oral Respiratory Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Boehringer Ingelheim acquires a potential first-in-class somatotaxin from the single-asset start-up Funxional Therapeutics.